The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

IMPORTANCE This study describes what is, to our knowledge, the previously unknown effect of glatiramer acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS). OBJECTIVE To determine whether glatiramer acetate therapy normalizes dysregulated B-cell proliferation and cytokine production in patients with MS. DESIGN, SETTING, AND PARTICIPANTS Twenty-two patients with MS who were receiving glatiramer acetate therapy and 22 treatment-naive patients with MS were recruited at The University of Texas Southwestern Medical Center MS clinic. Cell samples from healthy donors were obtained from HemaCare (Van Nuys, California) or Carter Blood Bank (Dallas, Texas). Treatment-naive patients with MS had not received any disease-modifying therapies for at least 3 months before the study. EXPOSURES Glatiramer acetate therapy for at least 3 months at the time of the study. MAIN OUTCOMES AND MEASURES B-cell phenotype and proliferation and immunoglobulin and cytokine secretion. RESULTS A restoration of interleukin 10 production by peripheral B cells was observed in patients undergoing glatiramer acetate therapy as well as a significant reduction of interleukin 6 production in a subset of patients who received therapy for less than 32 months. Furthermore, proliferation in response to high-dose CD40L was altered and immunoglobulin production was elevated in in vitro-activated B cells obtained from patients who received glatiramer acetate. CONCLUSIONS AND RELEVANCE Glatiramer acetate therapy remodels the composition of the B-cell compartment and influences cytokine secretion and immunoglobulin production. These data suggest that glatiramer acetate therapy affects several aspects of dysregulated B-cell function in MS that may contribute to the therapeutic mechanisms of glatiramer acetate.

[1]  A. Vissink,et al.  B-cell hyperactivity in primary Sjögren's syndrome , 2014, Expert review of clinical immunology.

[2]  R. Sobel,et al.  MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies , 2013, The Journal of experimental medicine.

[3]  V. Chalifa-Caspi,et al.  Gene expression analysis reveals functional pathways of glatiramer acetate activation , 2013, Expert opinion on therapeutic targets.

[4]  D. Isenberg,et al.  CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation , 2013, Science Translational Medicine.

[5]  Irene Puga,et al.  Activation of B cells by non‐canonical helper signals , 2012, EMBO reports.

[6]  Wei He,et al.  Aberrant CD40-Induced NF-κB Activation in Human Lupus B Lymphocytes , 2012, PloS one.

[7]  W. Leonard,et al.  Regulatory B Cells Control T Cell Autoimmunity Through IL-21-Dependent Cognate Interactions , 2012, Nature.

[8]  D. Gray,et al.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells , 2012, The Journal of experimental medicine.

[9]  L. Davis,et al.  Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity , 2012, Autoimmunity.

[10]  C. Weaver,et al.  Regulatory B10 Cells Differentiate into Antibody-Secreting Cells After Transient IL-10 Production In Vivo , 2012, The Journal of Immunology.

[11]  I. Sanz,et al.  OMIP‐003: Phenotypic analysis of human memory B cells , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[12]  Timothy Vollmer,et al.  Glatiramer Acetate‐Specific Antibody Titres in Patients with Relapsing / Remitting Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis , 2011, Scandinavian journal of immunology.

[13]  A. Haque,et al.  Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate , 2011, Journal of Neuroimmunology.

[14]  E. S. St. Clair,et al.  Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. , 2011, Blood.

[15]  M. Bagot,et al.  IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro , 2010, European journal of immunology.

[16]  Nitin J. Karandikar,et al.  Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein , 2010, European journal of immunology.

[17]  P. Calabresi,et al.  Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS? , 2010, Annals of neurology.

[18]  Alok Sharma,et al.  Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[19]  F. Shi,et al.  B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis , 2010, Experimental Neurology.

[20]  D. Isenberg,et al.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.

[21]  A. Achiron,et al.  Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis , 2009, Disease markers.

[22]  G. Bishop.  The many faces of CD40: multiple roles in normal immunity and disease. , 2009, Seminars in immunology.

[23]  J. Correale,et al.  Helminth infections associated with multiple sclerosis induce regulatory B cells , 2008, Annals of neurology.

[24]  M. Racke,et al.  Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis1 , 2006, The Journal of Immunology.

[25]  Ningli Li,et al.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Farina,et al.  Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. , 2004, Brain : a journal of neurology.

[27]  M. Duddy,et al.  Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.

[28]  P. Lipsky,et al.  Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus , 2004, Lupus.

[29]  M. Sela,et al.  Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy , 2003, Multiple sclerosis.

[30]  A. Lanzavecchia,et al.  A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. , 2003, Blood.

[31]  M. Kapsenberg,et al.  Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1 , 2003, The Journal of Immunology.

[32]  R. Koup,et al.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. , 2002, The Journal of clinical investigation.

[33]  J. Krieger,et al.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.

[34]  M. Sela,et al.  Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  P. Hjelmström,et al.  A Critical Role for Lymphotoxin in Experimental Allergic Encephalomyelitis , 1997, The Journal of experimental medicine.

[36]  M. Sela,et al.  Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. , 1997, International immunology.

[37]  M. Sela,et al.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Law,et al.  Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. , 2009, Advances in experimental medicine and biology.